How much profit has Inhibikase Therapeutics made this year?
Inhibikase Therapeutics has made -15.31 M USD this year.
In 2024, Inhibikase Therapeutics's profit amounted to -15.31 M USD, a -19.52% increase from the -19.03 M USD profit recorded in the previous year.
YEAR | NET INCOME (undefined USD) |
---|---|
2026e | - |
2025e | - |
2024e | - |
2023 | - |
2022 | - |
2021 | - |
2020 | - |
2019 | - |
2018 | - |
2017 | - |
2016 | - |
3 years
5 years
10 years
25 Years
Max
Gain insights into Inhibikase Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Inhibikase Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Inhibikase Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.
Observe the yearly bars to understand the annual performance and growth of Inhibikase Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
The expected values for the forthcoming years offer investors a glimpse into Inhibikase Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Leveraging the comparison between Revenue and EBIT helps in assessing Inhibikase Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Inhibikase Therapeutics’s growth potential.
Date | Inhibikase Therapeutics Revenue | Inhibikase Therapeutics EBIT | Inhibikase Therapeutics Net Income |
---|---|---|---|
2026e | 8.73 M undefined | -25.33 M undefined | -8.71 M undefined |
2025e | 0 undefined | -26.72 M undefined | -10.61 M undefined |
2024e | 0 undefined | -19.67 M undefined | -15.31 M undefined |
2023 | 260,500 undefined | -20.09 M undefined | -19.03 M undefined |
2022 | 120,000 undefined | -18.13 M undefined | -18.05 M undefined |
2021 | 3.1 M undefined | -14.77 M undefined | -14.79 M undefined |
2020 | 700,000 undefined | -2.82 M undefined | -2.85 M undefined |
2019 | 1.12 M undefined | -5.7 M undefined | -5.72 M undefined |
2018 | 4.04 M undefined | -2.12 M undefined | -2.15 M undefined |
2017 | 2.06 M undefined | -410,000 undefined | -440,000 undefined |
2016 | 970,000 undefined | -610,000 undefined | -630,000 undefined |
Revenue | EBIT | Net Income | |
---|---|---|---|
2016 | 970,000 USD | -610,000 USD | -630,000 USD |
2017 | 2.06 M USD | -410,000 USD | -440,000 USD |
2018 | 4.04 M USD | -2.12 M USD | -2.15 M USD |
2019 | 1.12 M USD | -5.7 M USD | -5.72 M USD |
2020 | 700,000 USD | -2.82 M USD | -2.85 M USD |
2021 | 3.1 M USD | -14.77 M USD | -14.79 M USD |
2022 | 120,000 USD | -18.13 M USD | -18.05 M USD |
2023 | 260,500 USD | -20.09 M USD | -19.03 M USD |
2024e | 0 USD | -19.67 M USD | -15.31 M USD |
2025e | 0 USD | -26.72 M USD | -10.61 M USD |
2026e | 8.73 M USD | -25.33 M USD | -8.71 M USD |
3 years
5 years
10 years
25 Years
Max
The gross margin, expressed as a percentage, delineates the gross profit made from the Inhibikase Therapeutics's sales revenue. A higher gross margin percentage indicates that the Inhibikase Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT margin represents the Inhibikase Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
The revenue margin demonstrates the Inhibikase Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Inhibikase Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Inhibikase Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Inhibikase Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Inhibikase Therapeutics Gross margin | Inhibikase Therapeutics Profit margin | Inhibikase Therapeutics EBIT margin | Inhibikase Therapeutics Profit margin |
---|---|---|---|
2026e | 0 % | -290.31 % | -99.86 % |
2025e | 0 % | 0 % | 0 % |
2024e | 0 % | 0 % | 0 % |
2023 | 0 % | -7,712.01 % | -7,304.75 % |
2022 | 0 % | -15,108.33 % | -15,041.67 % |
2021 | 0 % | -476.45 % | -477.1 % |
2020 | 0 % | -402.86 % | -407.14 % |
2019 | 0 % | -508.93 % | -510.71 % |
2018 | 0 % | -52.48 % | -53.22 % |
2017 | 0 % | -19.9 % | -21.36 % |
2016 | 0 % | -62.89 % | -64.95 % |
Gross margin | EBIT margin | Profit margin | |
---|---|---|---|
2016 | 0 % | -62.89 % | -64.95 % |
2017 | 0 % | -19.9 % | -21.36 % |
2018 | 0 % | -52.48 % | -53.22 % |
2019 | 0 % | -508.93 % | -510.71 % |
2020 | 0 % | -402.86 % | -407.14 % |
2021 | 0 % | -476.45 % | -477.1 % |
2022 | 0 % | -15,108.33 % | -15,041.67 % |
2023 | 0 % | -7,712.01 % | -7,304.75 % |
2024e | 0 % | 0 % | 0 % |
2025e | 0 % | 0 % | 0 % |
2026e | 0 % | -290.31 % | -99.86 % |
The profit margins of Inhibikase Therapeutics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Inhibikase Therapeutics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Evaluating Inhibikase Therapeutics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Inhibikase Therapeutics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
When Inhibikase Therapeutics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Inhibikase Therapeutics has made -15.31 M USD this year.
The profit has increased by -19.52% compared to last year fallen
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
Inhibikase Therapeutics publishes its earnings in the form of quarterly or annual reports.
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
The profits of Inhibikase Therapeutics are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
You can learn more about the earnings of Inhibikase Therapeutics by reviewing the quarterly or annual reports or following the company presentations.
Over the past 12 months, Inhibikase Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Inhibikase Therapeutics is expected to pay a dividend of 0 USD.
The current dividend yield of Inhibikase Therapeutics is .
Inhibikase Therapeutics pays a quarterly dividend. This is distributed in the months of .
Inhibikase Therapeutics paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
Inhibikase Therapeutics is assigned to the 'Health' sector.
To receive the latest dividend of Inhibikase Therapeutics from 8/22/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/22/2024.
The last dividend was paid out on 8/22/2024.
In the year 2023, Inhibikase Therapeutics distributed 0 USD as dividends.
The dividends of Inhibikase Therapeutics are distributed in USD.
Our stock analysis for Inhibikase Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Inhibikase Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.